Belief BioMed to Collaborate with AskBio to Explore Gene Therapy Potentials
Overview
To advance potential gene therapies in diseases with high unmet medical need, using a liver-targeted approach Belief BioMed Inc. (BBM), signed a new strategic collaboration with Asklepios BioPharmaceutical, Inc. (AskBio) to explore the potential for new gene therapies.
The Terms of the Contract
Under the terms of the contract, the companies will combine efforts and experience in gene therapy technology to explore potential therapies in diseases that may be treatable using a liver-targeted approach.
Statement from the CSO: Belief BioMed
Dr. Xiao Xiao, Co-founder, Chairman and Chief Science Officer of Belief BioMed, said, "Focusing on gene therapy, Belief BioMed has achieved exciting results in research, development and production since its inception.”
“The company's proprietary recombinant adeno-associated virus (rAAV) vector system has also been widely recognized by the industry. Our strategic partnership with AskBio is based on our shared vision, mutual trust and complementary resources and strength. With our joint effort we will be able to bring more innovative treatments in a timely manner to patients around the globe."
About the Company: AskBio
With global headquarters in North Carolina, US, AskBio is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives.
The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular, and metabolic disease indications.
The company has generated hundreds of proprietary capsids and promoters, several of which have entered pre-clinical and clinical testing.
The company: Belief BioMed
Belief BioMed is a biotech company that integrates the research & development, manufacturing, and clinical application of gene therapy products.
Its pipeline covers a wide range of therapeutic areas that include hemophilia, Duchenne Muscular Dystrophy (DMD), Parkinson's disease, and osteoarthritis.
This collaboration will further strengthen the company's core competitiveness in the field of gene therapy, and create a solid foundation for bringing additional new innovative gene therapies to patients worldwide.